GlassScriptPhysician profile
Sandra Kindness
NPI 1396069860
$587.04
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $502 · 2022: $85.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $126.59 | 2021 | |
| Biodelivery Sciences International, INC. | $80.54 | 2021 | |
| Collegium Pharmaceutical, INC. | $65.63 | 2021-2022 | |
| Incyte Corporation | $54.40 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.64 | 2021-2022 | |
| Janssen Biotech, INC. | $51.36 | 2021 | |
| Ucb, INC. | $50.15 | 2021 | |
| Abbvie INC. | $24.00 | 2022 | |
| Redhill Biopharma INC. | $17.40 | 2021 | |
| Merck Sharp & Dohme LLC | $16.94 | 2022 | |
| Amgen INC. | $16.65 | 2021 | |
| Nevro Corp. | $16.44 | 2022 | |
| Pfizer INC. | $14.30 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Kindness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.